Biocon Ltd. — Investor Presentation 2020

Sep 18, 2020

==> picture [109 x 43] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

September 18, 2020

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street,Mumbai – 400 001	To The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol- BIOCON

Dear Sir/Madam,

Sub: Investor Presentation on “Biocon Biologics Transforming Healthcare. Transforming Lives.”. Ref: Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

With reference to the captioned subject, please find enclosed Investor Presentation, presented at the Investor Meeting held on September 16, 2020.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above said information on record.

Thanking You,

Yours faithfully,

For Biocon Limited

==> picture [80 x 30] intentionally omitted <==

==> picture [64 x 67] intentionally omitted <==

___ Mayank Verma Company Secretary and Compliance Officer

Encl: Investor Presentation

==> picture [293 x 426] intentionally omitted <==

Biocon Biologics Transforming Healthcare. Transforming Lives. Investor Presentation September 2020

==> picture [292 x 59] intentionally omitted <==

1

==> picture [179 x 37] intentionally omitted <==

Safe Harbour

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the biotechnology and pharmaceuticals industries, changes in political conditions and changes in the foreign exchange control regulations. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition

==> picture [92 x 76] intentionally omitted <==

2

==> picture [179 x 37] intentionally omitted <==

Healthcare is a ‘Human Right’

~2B people, a third of the world’s population across developed and LMIC countries, lack access to essential medicines

Estimated Breast Cancer Time equivalent based treatment cost on avg. annual wages*

==> picture [530 x 220] intentionally omitted <==

----- Start of picture text -----

$18.5k ~10 years
$33.9k ~10 years
$71.7k ~1.7 years
----- End of picture text -----

Expected to be worsened post COVID-19 pandemic

*Not disposable income

Source: WHO Technical Report on Pricing of cancer medicines and its impacts (2019)

==> picture [41 x 308] intentionally omitted <==

Affordable Innovative Therapies

==> picture [92 x 76] intentionally omitted <==

3

==> picture [179 x 37] intentionally omitted <==

Platform built on 40+ years of strong heritage

Building an ecosystem where people are willing and able to continuously innovate

==> picture [363 x 279] intentionally omitted <==

----- Start of picture text -----

Insulins
rProteins mAbs
Others
Research &
Commercial
Development
Manufacturing
----- End of picture text -----*

==> picture [41 x 307] intentionally omitted <==

‘Pure Play’ Biosimilars Company

Fully integrated – lab to market Global Footprint

==> picture [381 x 43] intentionally omitted <==

----- Start of picture text -----

Disruptive collaborations
----- End of picture text -----

==> picture [92 x 76] intentionally omitted <==

*rProteins refers to Recombinant Proteins

4

==> picture [179 x 37] intentionally omitted <==

Ambition to transform global healthcare

Impact 5 million patient lives in FY22 by enabling access to more affordable healthcare solutions

==> picture [136 x 17] intentionally omitted <==

----- Start of picture text -----

Healthcare Spend
----- End of picture text -----

==> picture [397 x 246] intentionally omitted <==

----- Start of picture text -----

70%
Rx
Spend for
services
& others Traditional Pharma
approach
30%
Spend for
DTx
drugs
+
Rx
----- End of picture text -----

Re-imagined Patient Ecosystem

==> picture [41 x 308] intentionally omitted <==

Total G-CSF market volume (Europe)*

==> picture [333 x 312] intentionally omitted <==

----- Start of picture text -----

10.0
9.0
27% growth
7.9
8.0
7.4
6.8
7.0
6.4
6.2
6.0
6.0
5.0
4.0
2007 2008 2009 2010 2011 2012
Biosimilar introduced in Sep’08
No. of syringes (m)
----- End of picture text -----

*Includes filgrastim, pegfilgrastim and lenograstim

5

==> picture [179 x 37] intentionally omitted <==

Targeting a financially attractive global market

EU has already witnessed strong adoption of biosimilars while the US market has recently started picking up driving future growth

==> picture [858 x 357] intentionally omitted <==

----- Start of picture text -----

$53B
$48B
$34B
$33B
$27B
$18B
FY20 FY21 FY22 FY23 FY24 FY25
WW Biosimilars Market Size
Source: Management estimates based on originator company reported 2019 sales.
----- End of picture text -----

Source: Management estimates based on originator company reported 2019 sales.

6

==> picture [179 x 37] intentionally omitted <==

Developing ‘High Precision’ biosimilars at all scale Very well positioned with FDA approval of Insulins, mABs & Therapeutic Proteins

2 890+ R&D sites Patents granted* 28 7 Products Commercial in pipeline Products

==> picture [389 x 244] intentionally omitted <==

==> picture [61 x 32] intentionally omitted <==

==> picture [48 x 32] intentionally omitted <==

==> picture [48 x 32] intentionally omitted <==

==> picture [58 x 32] intentionally omitted <==

==> picture [63 x 32] intentionally omitted <==

==> picture [45 x 32] intentionally omitted <==

and over 100 other countries

==> picture [92 x 76] intentionally omitted <==

*Status Jun 2020

7

==> picture [179 x 37] intentionally omitted <==

Focusing on high-value therapeutic areas

Broad portfolio with majority of 28 biosimilars to be launched in the next decade

==> picture [876 x 377] intentionally omitted <==

----- Start of picture text -----

Stage Originator WW
Therapeutic
Molecule 2019 net sales
Areas
Early Dev./ Preclinical Phase I Phase III Planned Sub. / Filed Approved / Marketed ($ Bn)
Pegfilgrastim
Oncology
Trastuzumab
~20
Bevacizumab
Pertuzumab
Adalimumab
Immunology
Etanercept
~37
Undisclosed
Undisclosed
Glargine 100U
Diabetes
Glargine 300U
Aspart ~13
RHI^^
Undisclosed
Ophthalmology Undisclosed ~8
Bone Health Undisclosed ~5
----- End of picture text -----**

Partner Mylan has in-licensed product ( Biocon benefits from economic interest ); Japan is outside of Mylan partnership; ^^RHI completed Ph1 and considering potential Ph-3 waiver to be confirmed with FDA advice, shown as Planned submission. Note:* Mylan is responsible for commercialisation of all the disclosed products mentioned above except RHI in US and EU.

8

==> picture [179 x 37] intentionally omitted <==

Solid expertise in difficult-to-manufacture biologics

Understand the science, scale, scope & complexity of manufacturing biologics in a competitive cost structure

3 25+ Manufacturing sites cGMP approvals (2 Bangalore, 1 Malaysia) (incl. FDA & EMA)

Drug Substance, Drug Product & Device Capability

==> picture [330 x 194] intentionally omitted <==

Proprietary P. pastoris & mammalian CHO and NSO cell-based platform

Large-scale capacity catering to global needs

Robust regulatory compliance

==> picture [92 x 76] intentionally omitted <==

9

Providing access to more affordable biosimilars in over 120 countries

==> picture [179 x 37] intentionally omitted <==

On route to have increasing direct presence in key geographies

==> picture [822 x 407] intentionally omitted <==

----- Start of picture text -----

London
Boston
40+ Partners
Bangalore 35+ Distributors
Johor
Dubai
Singapore
Biocon Biologics product reach
Manufacturing
Sao Paulo
Commercial offices
Headquarter
‘Full legal entity registered but awaiting the CNPJ, the official identification numbers for companies
----- End of picture text -----

• ‘Full legal entity registered but awaiting the CNPJ, the official identification numbers for companies

10

Enabling access and healthcare cost optimisation with non-traditional approaches

==> picture [179 x 37] intentionally omitted <==

Global collaboration with Voluntis for development & distribution of a Digital Therapeutic for diabetics

Digitally-Enabled personalized insulin tomorrow

Insulin (Semglee) + Companion DTx (Insulia) = Optimised Therapy Patient Healthcare Outcomes Healthcare Costs

==> picture [55 x 42] intentionally omitted <==

==> picture [92 x 76] intentionally omitted <==

11

==> picture [179 x 37] intentionally omitted <==

Targeting $1 billion revenue by FY22 Building ‘commercial’ band-width to continuously strengthen performance

Recent and Upcoming Launches

==> picture [161 x 162] intentionally omitted <==

Bevacizumab & Aspart rH Insulin Digital Therapeutics Improve Market Share in Developed Markets Double-digit share in 9 markets ~16% of PFS market

Double-digit share in 9 markets #1 Biosimilar to Trastuzumab

Expand Presence in MoW Markets

==> picture [92 x 76] intentionally omitted <==

Most of World markets: 44% YoY growth in Q1’21

Note: Mylan responsible for commercialization of Semglee, Fulphila and Ogivri in US and EU.

12

==> picture [179 x 37] intentionally omitted <==

Biocon Biologics Transforming Healthcare, Transforming Lives.

==> picture [188 x 392] intentionally omitted <==

A vision driven by a strong belief that ‘healthcare is a human right’

Fully integrated global platform built on 40+ years of strong heritage

Operating in a sizeable global market with strong growth potential

Developing portfolio of 28 biosimilars across high-value therapeutic areas

Solid expertise in difficult-to-manufacture, large-scale, biologics

Commercial reach in 120+ countries with increasing direct presence

Highly experienced global management team setting out to achieve $1B by FY22

13